Aurinia vs. DifGen: Voclosporin Patent Suit Ends in Voluntary Dismissal
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Aurinia Pharmaceuticals, Inc. v. DifGen Pharmaceuticals LLC |
| Case Number | 1:25-cv-00530 (D. Del.) |
| Court | U.S. District Court for the District of Delaware |
| Duration | May 2025 – Jul 2025 77 days |
| Outcome | Plaintiff Voluntary Dismissal (Without Prejudice) |
| Patents at Issue | |
| Accused Products | DifGen’s generic versions of LUPKYNIS® (voclosporin) |
| Legal Representation | Aurinia: McCarter & English LLP (Alexandra M. Joyce, Daniel M. Silver, Maliheh Zare) |
In a swift resolution spanning just 77 days, Aurinia Pharmaceuticals, Inc. voluntarily dismissed its pharmaceutical patent infringement lawsuit against DifGen Pharmaceuticals LLC without prejudice — leaving the door open for future litigation while raising strategic questions across the branded drug and generic pharmaceutical industries.
Filed on May 1, 2025, in the U.S. District Court for the District of Delaware before Chief Judge Jennifer L. Hall, the case (No. 1:25-cv-00530) centered on two U.S. patents protecting Aurinia’s FDA-approved immunosuppressant drug LUPKYNIS® (voclosporin), indicated for lupus nephritis. DifGen, the defendant, was accused of developing generic versions of the voclosporin drug product alleged to infringe upon Aurinia’s protected intellectual property.
The case closed July 17, 2025, under Federal Rule of Civil Procedure 41(a)(1)(A)(i), with each party bearing its own attorneys’ fees and costs — a procedural outcome that offers no judicial ruling on the merits, yet carries significant strategic weight for pharmaceutical patent practitioners, IP professionals, and R&D teams monitoring the competitive landscape around branded specialty biologics and small-molecule immunosuppressants.
Case Overview
The Parties
⚖️ Plaintiff
Commercial-stage biopharmaceutical company best known for LUPKYNIS® (voclosporin), the first FDA-approved oral calcineurin inhibitor for active lupus nephritis.
🛡️ Defendant
Pharmaceutical development company engaged in the formulation and development of generic drug products, accused of infringing Aurinia’s voclosporin patents.
The Patents at Issue
Two U.S. patents protecting Aurinia’s FDA-approved immunosuppressant drug LUPKYNIS® (voclosporin) were asserted in this litigation:
- • U.S. Patent No. 11,622,991 B2 — A recently issued patent likely covering formulation, dosing regimen, or method-of-treatment claims related to voclosporin.
- • U.S. Patent No. 10,286,036 B2 — An earlier patent potentially covering foundational composition or pharmaceutical formulation claims.
Developing a generic product?
Check if your pharmaceutical formulation might infringe these or related patents.
The Verdict & Legal Analysis
Outcome
On July 17, 2025, Aurinia filed a voluntary dismissal of all claims against DifGen without prejudice pursuant to Federal Rule of Civil Procedure 41(a)(1)(A)(i). This allows Aurinia to exit litigation unilaterally with no judicial ruling on the merits, retaining the full right to re-file claims in the future. Each party bore its own attorneys’ fees and costs.
Verdict Cause Analysis
The case terminated pre-answer, so no claim construction rulings, validity determinations, or infringement findings were issued. The rapid 77-day resolution suggests that settlement-adjacent negotiations, licensing discussions, or strategic reassessments occurred rapidly off the docket. This could include a confidential licensing or market-entry agreement, Aurinia securing a 30-month statutory stay under Hatch-Waxman, or the patentee identifying claim scope limitations or prior art concerns.
Legal Significance
The without-prejudice dismissal carries notable strategic weight: it preserves Aurinia’s full litigation rights while generating zero unfavorable precedent on validity or infringement. For pharmaceutical patent holders, this is a tactically clean exit — no estoppel, no adverse claim construction, no royalty-setting precedent.
Strategic Takeaways
For patent holders: Voluntary pre-answer dismissal without prejudice preserves maximum optionality, allowing ongoing licensing discussions without locking the patentee into unfavorable judicial outcomes.
For accused infringers: The absence of a defendant attorney on record and the rapid dismissal timeline underscore the importance of appearing promptly and engaging proactively—even when plaintiffs signal potential willingness to resolve early.
For R&D and regulatory teams: This case illustrates how pharmaceutical patent enforcement can serve as a tactical signal even without litigation completion. Generic developers should conduct rigorous freedom-to-operate (FTO) analysis against multi-patent portfolios like Aurinia’s before committing to ANDA submissions or development resources.
Developing a robust patent strategy?
Learn from this case. Draft stronger claims and navigate pharmaceutical IP with confidence.
Industry & Competitive Implications
The Aurinia v. DifGen dispute reflects broader enforcement dynamics in the branded pharmaceutical sector, where companies protecting high-value, single-product revenue streams — like LUPKYNIS® for Aurinia — aggressively monitor and challenge generic entrants at the earliest stage of development.
LUPKYNIS® (voclosporin) occupies a specialized therapeutic niche in autoimmune disease treatment. With lupus nephritis representing a condition of significant unmet need and limited treatment alternatives, Aurinia’s patent portfolio surrounding voclosporin is commercially critical. Any successful generic entry would materially impact Aurinia’s revenue and market position.
The rapid dismissal suggests pharmaceutical patent disputes at this stage are increasingly resolved through private negotiation frameworks — a trend consistent with rising litigation costs, judicial capacity constraints, and the commercial preference for licensing over protracted infringement battles.
For companies developing generic specialty drugs, this case reinforces that early engagement with branded patent holders — whether through licensing discussions or patent challenge proceedings at the USPTO (IPR petitions) — may be more efficient than awaiting litigation outcomes. For branded manufacturers, it demonstrates the value of maintaining broad, layered patent portfolios that create multiple enforcement leverage points.
Power Your Patent Strategy with Eureka IP
From novelty searches to patent drafting, Eureka’s AI-powered tools help you navigate the patent landscape with confidence.
⚠️ Freedom to Operate (FTO) Analysis in Pharma
This case highlights critical IP risks in pharmaceutical product development. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation for pharmaceutical IP.
- View related patents in the voclosporin technology space
- See which companies are active in lupus nephritis IP
- Understand claim construction patterns for pharma patents
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own generic drug or pharmaceutical product.
- Input your product’s API, formulation, or method of treatment
- AI identifies potentially blocking pharmaceutical patents
- Get actionable risk assessment report for your pipeline
High Risk Area
Voclosporin API, formulation & methods
2 Key Patents
Asserted in this specific case
ANDA Strategy
Critical for generic market entry
✅ Key Takeaways
For Patent Attorneys & Litigators
Rule 41(a)(1)(A)(i) dismissal without prejudice creates zero adverse precedent and preserves full re-filing rights — a strategic tool in pharmaceutical patent enforcement.
Search related case law →Delaware District Court remains the premier venue for pharmaceutical patent disputes, including pre-ANDA enforcement actions.
Explore precedents →Absence of defendant counsel at dismissal may indicate pre-appearance resolution — monitor for follow-on filings or licensing disclosures.
Get litigation alerts →For IP Professionals
Aurinia’s multi-patent assertion strategy (two patents, one product) reflects best practices in layered pharmaceutical IP portfolio management.
Analyze patent portfolios →Monitor U.S. Patent Nos. 11,622,991 and 10,286,036 for continuation applications, reexamination proceedings, or IPR petitions that may reshape the voclosporin patent landscape.
Track patent legal status →For R&D Teams
Generic developers targeting branded specialty drugs should conduct comprehensive FTO analysis across full patent families — not just lead patents — before ANDA filing.
Start FTO analysis for my product →A 77-day dismissal without prejudice does not signal clear freedom to operate; re-filing risk remains active.
Assess infringement risk →Consider early engagement with branded patent holders through licensing discussions or USPTO patent challenge proceedings.
View competitor strategies →❓ FAQ
What patents were involved in Aurinia v. DifGen?
The case involved U.S. Patent No. 11,622,991 B2 (App. No. 17/713,140) and U.S. Patent No. 10,286,036 B2 (App. No. 15/835,219), both related to Aurinia’s LUPKYNIS® (voclosporin) drug product.
What was the basis for dismissal in Case No. 1:25-cv-00530?
Aurinia filed a voluntary dismissal without prejudice under Federal Rule of Civil Procedure 41(a)(1)(A)(i) on July 17, 2025, with each party bearing its own attorneys’ fees. No merits ruling was issued.
How might this case affect voclosporin generic patent litigation?
The without-prejudice dismissal preserves Aurinia’s right to re-file, leaving generic entrants without judicial clarity on patent validity or infringement — reinforcing the need for robust FTO analysis in this therapeutic space.
Ready to Strengthen Your Patent Strategy?
Join thousands of IP professionals using Eureka to conduct prior art searches, draft patents, and analyze competitive landscapes.